Autres langues Merck & Co., Inc.

Actions

MRK

US58933Y1055

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 22:04:18 20/05/2026			Varia. 5j.	Varia. 1 janv.
113,74 ^USD	-0,43%		-0,01%	+7,77%

20:26	Le National Advertising Review Board saisit la FTC et la FDA concernant les allégations de dosage du Bravecto Quantum de Merck Animal Health	RE
16:14	Secteur pharma : l'IA au coeur des stratégies pour réduire les coûts et les délais	RE

Autres langues

20:26	National Advertising Review Board refers Merck animal health to FTC & FDA for Bravecto Quantum dosing claims
17:02	Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
16:14	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
19/05	Nvidia: ¿lo logrará otra vez?
19/05	Kann Nvidia es erneut schaffen?
19/05	Can Nvidia Do It Again?
19/05	Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial
19/05	WHO besorgt über rasche Ebola-Ausbreitung - US-Patient kommt nach Deutschland
19/05	Morning Meeting: Die Börse reagiert empfindlich auf Zinserhöhungen
18/05	Global markets live: Merck, Regeneron, Ford, Lululemon, Brambles…
18/05	Regeneron drops after skin cancer treatment fails late-stage trial
18/05	Merck Says Endometrial Cancer Therapy Meets Primary Endpoints in Phase 3 Trial
18/05	Merck's drug helps uterine cancer patients live longer in late-stage trial
18/05	Merck's endometrial cancer drug meets late-stage trial goals
18/05	Merck announces TroFuse-005 trial evaluating sacituzumab tirumotecan met primary endpoints of overall survival and progression-free survival in certain patients with advanced or recurrent endometrial cancer
18/05	Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer
18/05	Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints in Advanced or Recurrent Endometrial Cancer
18/05	Regeneron drops after skin cancer treatment misses late-stage trial goal
18/05	Morning Meeting: Der neue wichtigste Mann der Welt
15/05	Mubadala Investment Co PJSC reports share stake in Apple, Medtronic, Broadcom
13/05	Las acciones europeas suben impulsadas por valores mineros y tecnológicos
13/05	Wall Street erhält die Quittung
13/05	Merck in Bestform, Adecco zeigt Schwäche, Siemens Energy mit Rückenwind
13/05	European shares lifted by miners and tech; Mideast in focus
12/05	Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at Asco 2026